Results 191 to 200 of about 416,036 (340)

Cisplatin-Loaded M1 Macrophage-Derived Vesicles Have Anti-Cancer Activity in Osteosarcoma. [PDF]

Cells
Anand N, McCorkle JR, Schweer DS, Li L, Hill KS, Fath MA, Allison DB, Richards CL, Kolesar JM.   +8 more
europepmc   +1 more source

Dose-response curves for the antiemetic potency and for the side effects of metoclopramide (MCL) against cisplatin induced emesis. [PDF]

, 1986
Reinhard Saller, D. Hellenbrecht, A. Hellstern, P.S. Mitrou   +3 more
openalex   +1 more source

Engineering Metal‐Organic‐Framework‐Based STING Nanoagonists for PROTAC‐Enhanced Cancer Chemo‐Metalloimmunotherapy

Advanced Science, EarlyView.
Schematic overview of PROTAC‐enhanced chemo‐metalloimmunotherapy, integrating senescence induction, multi‐modal STING pathway activation, PD‐L1 blockade, and immune amplification via coordinated PROTACs, metal ions, and chemotherapy to elicit robust antitumor immunity and circumvent immune evasion.
Zhenzhen Chen, Zhe Feng, Siyuan Wang, Jingjing Zhang   +3 more
wiley   +1 more source

The effects of platinum levels in plasma, urine, and kidney on blood urea nitrogen levels after cisplatin injection in rats.

, 1988
Jiro Uozumi, Charles L. Litterst
openalex   +2 more sources

Long‐Term Survival of Two Versus Three Courses of Preoperative Cisplatin and Fluorouracil Plus Docetaxel for Locally Advanced Esophageal Cancer: A Multicenter Randomized Phase II Trial

Annals of Gastroenterological Surgery, EarlyView.
This multi‐institutional, randomized, phase II trial aimed to investigate the long‐term survival outcomes of two versus three courses of DCF for locally advanced esophageal squamous cell carcinoma (ESCC). The 5‐year overall survival and progression‐free survival rates for the three and two course groups were 70.7% vs. 63.8% (hazard ratio (HR) = 0.91, p 
Takahito Sugase, Hiroshi Miyata, Takashi Kanemura, Norihiro Matsuura, Tomoki Makino, Makoto Yamasaki, Koji Tanaka, Kotaro Yamashita, Kota Momose, Osamu Shiraishi, Keijiro Sugimura, Masaaki Motoori, Kazumasa Fujitani, Atsushi Takeno, Motohiro Hirao, Yutaka Kimura, Taroh Satoh, Masahiko Yano, Yuichiro Doki, Takushi Yasuda   +19 more
wiley   +1 more source

Case Report: Life-threatening cisplatin-induced myelosuppression in pediatric osteosarcoma: molecular mechanisms, pharmacogenomic profiling, and targeted clinical management. [PDF]

Front Pharmacol
Dai C, Zhang Y, Zhang Y, Dong Y.
europepmc   +1 more source

Bronchial arterial infusion of cisplatin for lung cancer and platinum concentration in the tumor.

, 1988
Hideo Masuda, Toshiro Ogata, Keiichi Kikuchi, Keigo Takagi, Ken Shimizu, Kuniaki Nakanishi, Seiichi Tamai   +6 more
openalex   +2 more sources

Essential Updates 2023/2024: Recent Advances of Multimodal Approach in Patients for Gastric Cancer

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Gastric cancer remains a major global health burden, especially in East Asia. Recent years have brought significant advances in multimodal management, including surgery, perioperative chemotherapy, immunotherapy, and supportive care. This review summarizes key updates from 2023 to 2024, focusing on surgical innovations, perioperative systemic ...
Katsutoshi Shoda, Yoshihiko Kawaguchi, Suguru Maruyama, Daisuke Ichikawa   +3 more
wiley   +1 more source

Epithelial‑mesenchymal plasticity and cisplatin resistance in germ cell tumors: Mechanisms and emerging therapeutic strategies (Review). [PDF]

Int J Oncol
Gomes ESB, De Souza TM, Oliveira ALP, Bezerra AFSP, Cardoso IIV, Silva L, Lopes LF, Rosa MN, Pinto MT.   +8 more
europepmc   +1 more source

Human nucleotide excision repairin vitro: repair of pyrimidine dimers, psoralen and cisplatin adducts by HeLa cell-free extract

, 1989
Sibghat-Ullah, Intisar Husain, Wendi Carlton, A Sancar   +3 more
openalex   +2 more sources